Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Rent the Runway Inc (RENT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Rent the Runway Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Rent the Runway Inc trades at $3.4 (market cap $115.40M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 38.9× Rent the Runway Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | RENT | |
|---|---|---|
Market Cap | $4.49B | $115.40M |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $9.39 |
52-Week Low | $20.06 | $3.10 |
Enterprise Value | $3.69B | $275.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
RENT trades at $3.42, down 0.87% on the day, with a bearish technical signal. The company reported Q1 2026 revenue of $89.9 million, up 29.2% year-over-year, but continues to post net losses. Valuation ratios appear low with a P/E of 0.43 and P/S of 0.18, while negative equity of -$182.5 million and high debt levels pose financial risks. Recent leadership changes include the appointment of an interim CEO.
The outlook is mixed: strong revenue growth and low valuations suggest potential upside, but persistent losses, negative equity, and high leverage present significant risks. Analyst consensus is divided with 42% buy ratings, though no sell ratings exist. The stock's direction hinges on achieving profitability and managing debt.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
